ClinicalTrials.gg
CompletedNCT02363998NU LEAFUpdated Mar 22, 2022Results posted

Open-Label, Safety Study of Lofexidine

A Phase 3 interventional study of Lofexidine in Opioid Withdrawal, sponsored by USWM, LLC (dba US WorldMeds). Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-22.

Sponsored by USWM, LLC (dba US WorldMeds) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.

Read the detailed description

Eligible subjects (person seeking treatment for partial or total opioid withdrawal) enrolled in this study are required to take lofexidine for a minimum of 7 days.

02

Conditions studied

  • Opioid Withdrawal

Keywords

  • detoxification
  • agonist taper
  • methadone step down
  • buprenorphine step down
  • opioid withdrawal syndrome
03

In context

Lead sponsor

USWM, LLC (dba US WorldMeds) is the lead sponsor of 17 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female at least 18 years of age
  • Must be able to verbalize understanding of the consent form, able to provide written , and verbalize willingness to complete study procedures
  • Must have current dependence, according to the Mini International Neuropsychiatric Interview (M.I.N.I.), on any opioid (including methadone and buprenorphine maintenance treatment)
  • Must be seeking treatment for partial or total withdrawal from current opioid and expected, as determined by the Principal Investigator, to benefit from lofexidine treatment for at least 7 days at doses. This can include a variety of clinical situations where opioid withdrawal illness is likely to occur including abrupt and total withdrawal (including from methadone and buprenorphine), agonist-assisted total withdrawal, dose reduction of maintenance treatment (e.g., methadone, buprenorphine) and transition from an opioid agonist to naltrexone or buprenorphine maintenance
  • Must have Urine toxicology screen result of positive for opioid(s) relevant to the subject's withdrawal treatment goal
  • If female and of , subject must agree to use of one of the following methods of including oral contraceptives, patch, barrier (diaphragm, sponge or condom) plus spermicidal preparations, intrauterine contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, hormonal vaginal contraceptive ring or surgical sterilization or partner sterile (with documented proof)

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant or lactating
  • History of very serious medical illness not under control including, but not limited to, active self-reported acquired immune deficiency syndrome (AIDS) or self-reported (HIV) positive status and taking retroviral medications currently or within the past 4 weeks and/or having an unstable psychiatric condition. These conditions will be determined at Screening by medical history, physical examination, 12 lead (duplicate), clinical laboratory tests for infectious diseases, and a tuberculin test
  • Current dependence (based on the M.I.N.I.) on any psychoactive substance (excluding caffeine, nicotine, and the subject's current opioid-dependence agent, which can include methadone and buprenorphine, for example, in agonist-maintained subjects) that requires detoxification or dose reduction as part of the pre-defined individual subject withdrawal treatment goal
  • Have participated in an drug study within the past 30 days
  • Have a history of lofexidine exposure in a prior clinical trial or otherwise
  • Have an abnormal cardiovascular exam at screening
  • Any subject that requires tricyclic antidepressants, which may reduce the efficacy of imidazoline derivatives and/or beta-receptor blockers, to avoid the risk of excessive bradycardia
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Other
    Open Label Lofexidine

    During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.

    Drug: Lofexidine

Interventions

  • All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.

    Also known as: Lofexidine hydrochloride (HCL)

06

What researchers measure

Primary outcomes

  1. Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Subjects with at least 1 TEAE occurring on days 1-14.

    Time frame: Days 1-14

  2. Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)

    Time frame: Days 1-14

  3. Overall Treatment Emergent Adverse Events (TEAEs) by Severity

    Time frame: Days 1-14

  4. Occurrence of Per Protocol Adverse Events of Special Interest (AESI)

    Time frame: Day 1 to Day 14

  5. Occurrence of Adverse Events (AEs) Not Related to Opioid Withdrawal

    Time frame: Day 1 to Day 14

  6. Mean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital Sign

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  7. Mean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital Sign

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  8. Mean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital Sign

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  9. Mean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital Sign

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  10. Mean Observed and Change From Screening in Seated Pulse (Bpm): Vital Signs

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  11. Mean Observed and Change From Screening in Standing Pulse (Bpm): Vital Signs

    Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

    Time frame: Day 1 to Day 14

  12. Columbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior Numbers

    The C-SSRS measures both suicidal ideation and suicidal behavior and will be completed to assess lifetime suicidality before first dose of study drug, 3.5 hours after first daily dose of study drug on in-clinic treatment days, and then once a day before dosing during outpatient treatment days. C-SSRS will also be assessed at end of study/discontinuation.

    Time frame: Day 1 to Day 14

  13. Clinical Laboratory Test Change From Baseline: Hematology

    Hematology Parameters with Shifts in ≥3% of Subjects from Screening to End of Study

    Time frame: Day 1 to Day 14

  14. Clinical Laboratory Test Change From Baseline: Chemistry

    Chemistry Parameters with Shifts in ≥3% of Subjects from Screening to End of Study

    Time frame: Day 1 to Day 14

  15. Clinical Laboratory Test Change From Baseline: Urinalysis

    Time frame: Day 1 to Day 7

  16. Safety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of Study

    For each 12-lead ECG obtained during the study, the investigator made an overall interpretation of the ECG (normal, abnormal NCS, and abnormal CS). Shifts from normal at baseline to abnormal NCS and abnormal CS at the end of study predose and postdose assessments were summarized.

    Time frame: Day 1 and Day 14

07

Results

Posted Apr 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneOL: Lofexidine HCl
Started286
Completed168
Not completed118

Outcome measures

PrimaryOverall Occurrence of Treatment Emergent Adverse Events (TEAEs)

Subjects with at least 1 TEAE occurring on days 1-14.

Time frame:
Days 1-14
Reported as:
Count of participants · Participants
Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)
ParticipantsOL: Lofexidine HCl
Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)270
PrimaryOverall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)
Time frame:
Days 1-14
Reported as:
Count of participants · Participants
Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)
ParticipantsOL: Lofexidine HCl
Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)2
PrimaryOverall Treatment Emergent Adverse Events (TEAEs) by Severity
Time frame:
Days 1-14
Reported as:
Count of participants · Participants
Overall Treatment Emergent Adverse Events (TEAEs) by Severity
ParticipantsOL: Lofexidine HCl
Mild104
Moderate158
Severe8
PrimaryOccurrence of Per Protocol Adverse Events of Special Interest (AESI)
Time frame:
Day 1 to Day 14
Reported as:
Count of participants · Participants
Occurrence of Per Protocol Adverse Events of Special Interest (AESI)
ParticipantsOL: Lofexidine HCl
Orthostatic hypotension96
Orthostatic bradycardia0
Syncope1
PrimaryOccurrence of Adverse Events (AEs) Not Related to Opioid Withdrawal
Time frame:
Day 1 to Day 14
Reported as:
Count of participants · Participants
Occurrence of Adverse Events (AEs) Not Related to Opioid Withdrawal
ParticipantsOL: Lofexidine HCl
Opioid Withdrawal Related Adverse Events233
Non-Opioid Withdrawal Related Adverse Events208
PrimaryMean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital Sign

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · mmHg
Mean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital Sign
mmHgInpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Screening121.9 ± 11.85————————
Day 1 Observed122.2 ± 13.89109.7 ± 15.47111.1 ± 16.07112.6 ± 15.91114.1 ± 15.38116.9 ± 17.94116.7 ± 16.82——
Day 1 Change—-12.2 ± 15.25-10.8 ± 15.21-9.4 ± 16.05-8.0 ± 15.12-5.2 ± 19.16-5.3 ± 17.69——
Day 2 Observed116.8 ± 15.77114.8 ± 15.82114.5 ± 14.30115.7 ± 16.20117.4 ± 16.55119.7 ± 18.01117.9 ± 16.04——
Day 2 Change-5.0 ± 16.21-7.0 ± 15.65-7.3 ± 15.53-6.2 ± 16.43-4.5 ± 17.10-2.1 ± 18.03-3.9 ± 17.24——
Day 3 Observed116.0 ± 15.66116.1 ± 15.75114.3 ± 14.71116.9 ± 16.21116.9 ± 15.90118.2 ± 16.64117.1 ± 15.70——
Day 3 Change-5.9 ± 16.38-5.8 ± 16.22-7.5 ± 16.40-5.0 ± 17.30-5.0 ± 16.88-3.8 ± 17.08-4.9 ± 16.17——
Day 4 Observed116.2 ± 15.32113.7 ± 14.26114.4 ± 14.85118.6 ± 14.77118.7 ± 14.68120.0 ± 15.24117.7 ± 13.90117.0 ± 12.44115.7 ± 8.60
Day 4 Change-6.0 ± 15.47-8.1 ± 14.65-7.7 ± 14.77-3.7 ± 15.31-3.0 ± 15.24-1.8 ± 16.36-4.0 ± 16.10-4.7 ± 14.54-5.5 ± 11.15
Day 5 Observed115.4 ± 14.76114.8 ± 15.06115.2 ± 13.69116.3 ± 15.72117.1 ± 14.78117.2 ± 14.62117.0 ± 13.48116.7 ± 12.12118.3 ± 11.06
Day 5 Change-6.3 ± 15.86-7.1 ± 16.87-6.6 ± 15.46-5.6 ± 16.76-4.8 ± 16.64-4.8 ± 15.46-4.9 ± 14.93-6.3 ± 16.02-4.7 ± 14.97
Day 6 Observed115.2 ± 16.13113.4 ± 14.81114.0 ± 14.52116.8 ± 16.74116.6 ± 15.03117.5 ± 16.57118.4 ± 16.46118.7 ± 15.19122.0 ± 15.14
Day 6 Change-6.5 ± 15.89-8.7 ± 14.74-8.0 ± 14.88-5.1 ± 16.57-5.5 ± 15.10-4.5 ± 17.13-3.5 ± 15.41-3.6 ± 18.440.4 ± 19.39
Day 7 Observed118.0 ± 16.44116.4 ± 14.82114.9 ± 15.45117.9 ± 11.32117.9 ± 12.20121.1 ± 14.84118.5 ± 12.08120.8 ± 12.99116.3 ± 9.96
Day 7 Change-4.4 ± 16.50-5.4 ± 14.82-5.1 ± 12.87-3.0 ± 13.44-3.0 ± 11.430.2 ± 15.23-1.7 ± 16.302.6 ± 16.29-5.1 ± 12.91
Day 8 Observed———————118.4 ± 11.69122.8 ± 13.15
Day 8 Change———————-2.8 ± 14.032.1 ± 13.41
Day 9 Observed———————124.3 ± 13.14122.3 ± 16.51
Day 9 Change———————3.6 ± 14.431.4 ± 14.75
Day 10 Observed———————122.2 ± 14.41124.3 ± 17.24
Day 10 Change———————1.2 ± 14.123.6 ± 17.67
Day 11 Observed———————121.2 ± 12.54125.1 ± 14.16
Day 11 Change———————0.7 ± 13.524.6 ± 15.39
Day 12 Observed———————126.3 ± 9.75120.4 ± 12.22
Day 12 Change———————4.3 ± 9.20-1.4 ± 12.10
Day 13 Observed———————124.8 ± 12.48123.5 ± 10.61
Day 13 Change———————4.0 ± 13.623.0 ± 14.38
Day 14 Observed———————128.0 ± 12.62—
Day 14 Change———————7.6 ± 10.80—
PrimaryMean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital Sign

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · mmHg
Mean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital Sign
mmHgInpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Day 1 Observed120.4 ± 13.94105.7 ± 16.70107.9 ± 16.43106.7 ± 15.66108.2 ± 16.37108.7 ± 15.75109.0 ± 16.93——
Day 1 Change—-16.8 ± 16.80-14.3 ± 15.95-15.8 ± 16.48-14.7 ± 15.80-13.9 ± 17.31-13.6 ± 17.74——
Day 2 Observed112.4 ± 15.85108.5 ± 15.94108.0 ± 15.06108.6 ± 16.90109.8 ± 16.22110.4 ± 17.70110.7 ± 16.07——
Day 2 Change-10.0 ± 16.32-14.0 ± 17.24-14.7 ± 16.29-14.1 ± 17.11-13.0 ± 17.07-12.2 ± 17.69-11.9 ± 16.91——
Day 3 Observed111.2 ± 16.61108.1 ± 17.15109.1 ± 15.40107.8 ± 15.97110.0 ± 15.99110.8 ± 15.77110.5 ± 16.19——
Day 3 Change-11.4 ± 16.25-14.4 ± 17.22-13.5 ± 15.73-14.8 ± 17.63-12.6 ± 17.16-11.9 ± 16.61-12.2 ± 16.09——
Day 4 Observed112.4 ± 15.93107.9 ± 16.18110.9 ± 17.93109.7 ± 14.74112.4 ± 15.12111.7 ± 15.81111.1 ± 14.79116.6 ± 15.11113.4 ± 11.60
Day 4 Change-10.3 ± 15.29-14.4 ± 15.07-11.9 ± 16.69-13.2 ± 15.66-9.9 ± 15.25-10.8 ± 16.21-11.3 ± 15.89-6.1 ± 17.61-8.8 ± 13.77
Day 5 Observed111.3 ± 15.97108.9 ± 15.41109.2 ± 14.75109.5 ± 15.75110.8 ± 14.72110.2 ± 16.55111.4 ± 15.49114.6 ± 12.29116.1 ± 10.69
Day 5 Change-11.1 ± 15.19-13.6 ± 15.83-13.2 ± 16.10-13.0 ± 17.91-11.7 ± 16.44-12.3 ± 17.23-11.0 ± 16.42-8.4 ± 14.43-7.5 ± 15.02
Day 6 Observed112.2 ± 16.44108.8 ± 15.61110.2 ± 15.25109.1 ± 16.83110.7 ± 16.44110.9 ± 16.91112.7 ± 16.24116.6 ± 15.47116.4 ± 16.05
Day 6 Change-10.4 ± 16.12-14.0 ± 17.01-12.6 ± 15.30-13.8 ± 17.45-12.3 ± 16.78-12.0 ± 17.84-10.0 ± 16.10-5.8 ± 17.68-5.8 ± 18.68
Day 7 Observed113.9 ± 17.10113.9 ± 14.96110.1 ± 17.41110.1 ± 15.32112.7 ± 13.26114.6 ± 16.42111.6 ± 14.00118.0 ± 13.00116.6 ± 15.53
Day 7 Change-8.7 ± 17.74-8.2 ± 16.40-8.8 ± 16.55-9.6 ± 17.71-6.8 ± 14.10-4.6 ± 17.96-7.3 ± 17.01-4.6 ± 15.53-5.8 ± 19.56
Day 8 Observed———————117.8 ± 11.13117.6 ± 13.94
Day 8 Change———————-2.8 ± 13.53-2.5 ± 18.18
Day 9 Observed———————119.4 ± 10.62119.5 ± 17.05
Day 9 Change———————-0.8 ± 13.27-0.9 ± 21.35
Day 10 Observed———————122.3 ± 14.78121.9 ± 18.78
Day 10 Change———————1.6 ± 15.461.6 ± 22.89
Day 11 Observed———————123.7 ± 14.91123.2 ± 14.43
Day 11 Change———————3.0 ± 16.201.8 ± 18.90
Day 12 Observed———————124.3 ± 11.19118.4 ± 14.06
Day 12 Change———————2.0 ± 12.76-4.1 ± 16.91
Day 13 Observed———————122.7 ± 11.77125.1 ± 12.25
Day 13 Change———————1.0 ± 14.583.5 ± 16.41
Day 14 Observed———————128.8 ± 9.89—
Day 14 Change———————7.8 ± 9.92—
PrimaryMean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital Sign

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · mmHg
Mean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital Sign
mmHgInpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Day 1 Observed78.3 ± 8.8969.4 ± 10.9569.3 ± 10.3470.8 ± 11.1371.5 ± 10.7673.5 ± 12.1872.8 ± 12.26——
Day 1 ChangeNA ± NA-7.8 ± 10.78-7.9 ± 9.88-6.3 ± 11.49-5.7 ± 10.80-3.7 ± 12.52-4.3 ± 12.55——
Day 2 Observed73.8 ± 10.4972.2 ± 10.8972.2 ± 10.2073.4 ± 11.5373.7 ± 12.0875.4 ± 11.6774.0 ± 11.44——
Day 2 Change-3.3 ± 10.73-4.9 ± 11.17-5.0 ± 10.61-3.8 ± 11.38-3.4 ± 12.04-1.8 ± 12.19-3.3 ± 12.11——
Day 3 Observed73.7 ± 11.0573.2 ± 10.5971.4 ± 10.0573.0 ± 10.4872.9 ± 10.6473.2 ± 11.3273.5 ± 11.08——
Day 3 Change-3.6 ± 11.60-4.0 ± 10.97-5.8 ± 10.88-4.1 ± 10.32-4.3 ± 10.56-4.0 ± 11.41-3.8 ± 11.37——
Day 4 Observed73.9 ± 10.5571.4 ± 10.2870.9 ± 11.1174.7 ± 10.3973.7 ± 10.1074.0 ± 10.9573.4 ± 9.7875.0 ± 8.5771.7 ± 8.53
Day 4 Change-3.2 ± 11.06-5.7 ± 10.75-6.4 ± 10.48-2.6 ± 10.27-3.3 ± 9.74-3.1 ± 11.75-3.6 ± 10.51-3.0 ± 10.65-6.1 ± 10.68
Day 5 Observed73.2 ± 10.4271.5 ± 10.2571.7 ± 10.3872.7 ± 10.5871.8 ± 10.1473.1 ± 9.9772.3 ± 10.4472.6 ± 9.9972.8 ± 10.67
Day 5 Change-3.8 ± 11.17-5.4 ± 11.75-5.1 ± 10.59-4.2 ± 10.38-5.0 ± 10.79-3.7 ± 10.77-4.7 ± 10.56-5.6 ± 11.18-6.0 ± 12.01
Day 6 Observed72.2 ± 10.3369.8 ± 10.4670.8 ± 10.8172.2 ± 10.0872.6 ± 11.0272.8 ± 11.3572.0 ± 11.2974.2 ± 11.2576.8 ± 9.99
Day 6 Change-4.6 ± 9.87-7.0 ± 10.86-6.0 ± 11.42-4.6 ± 10.46-4.3 ± 10.77-4.0 ± 11.05-4.9 ± 11.51-3.9 ± 12.17-1.4 ± 12.90
Day 7 Observed72.9 ± 10.6374.3 ± 9.9071.5 ± 11.1870.2 ± 10.4070.0 ± 9.0973.1 ± 9.6269.8 ± 8.0476.1 ± 9.3071.8 ± 8.90
Day 7 Change-3.6 ± 11.56-3.5 ± 10.59-4.8 ± 12.01-6.9 ± 10.96-7.6 ± 10.25-4.5 ± 10.21-7.5 ± 12.94-2.6 ± 11.32-7.6 ± 14.12
Day 8 Observed———————73.5 ± 9.2373.9 ± 11.18
Day 8 Change———————-4.1 ± 10.98-3.5 ± 13.10
Day 9 Observed———————75.5 ± 9.3874.0 ± 11.92
Day 9 Change———————-1.7 ± 10.71-3.5 ± 12.63
Day 10 Observed———————74.6 ± 9.4475.8 ± 12.46
Day 10 Change———————-2.4 ± 9.31-1.2 ± 12.34
Day 11 Observed———————75.7 ± 10.3776.3 ± 8.99
Day 11 Change———————-0.9 ± 11.57-0.4 ± 10.87
Day 12 Observed———————77.3 ± 8.0176.6 ± 8.26
Day 12 Change———————0.6 ± 10.39-0.5 ± 9.47
Day 13 Observed———————77.2 ± 8.2277.9 ± 8.98
Day 13 Change———————1.3 ± 10.942.0 ± 13.71
Day 14 Observed———————78.4 ± 7.81—
Day 14 Change———————3.5 ± 9.72—
PrimaryMean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital Sign

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · mmHg
Mean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital Sign
mmHgInpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Day 1 Observed79.8 ± 8.6568.8 ± 11.3470.3 ± 11.0369.8 ± 11.8770.7 ± 11.2571.0 ± 11.1270.4 ± 11.68——
Day 1 Change—-11.1 ± 11.58-9.5 ± 11.26-10.0 ± 12.57-9.4 ± 11.73-8.9 ± 12.71-9.6 ± 12.92——
Day 2 Observed73.4 ± 11.0270.7 ± 11.2071.0 ± 11.4871.6 ± 11.8572.2 ± 11.7872.3 ± 12.2771.8 ± 11.52——
Day 2 Change-6.5 ± 11.83-9.4 ± 12.26-9.1 ± 12.74-8.5 ± 12.48-7.9 ± 13.00-7.9 ± 13.44-8.4 ± 13.05——
Day 3 Observed74.0 ± 12.0370.6 ± 11.9070.0 ± 10.5370.0 ± 10.6270.8 ± 10.7771.3 ± 10.6971.5 ± 10.90——
Day 3 Change-6.2 ± 12.37-9.4 ± 13.09-10.0 ± 11.74-10.1 ± 11.91-9.3 ± 12.00-8.8 ± 11.91-8.7 ± 11.78——
Day 4 Observed73.2 ± 11.8070.6 ± 11.1171.2 ± 11.1271.5 ± 10.9872.2 ± 10.5971.2 ± 11.0971.8 ± 10.1475.7 ± 10.4570.1 ± 10.26
Day 4 Change-7.0 ± 12.08-9.4 ± 11.90-9.2 ± 11.96-8.9 ± 12.91-8.0 ± 11.71-9.0 ± 12.64-8.2 ± 11.46-4.5 ± 13.21-10.0 ± 11.81
Day 5 Observed72.4 ± 10.0470.0 ± 10.4670.7 ± 10.7670.3 ± 10.9971.1 ± 11.3870.2 ± 11.2071.1 ± 10.9474.8 ± 9.7974.5 ± 10.44
Day 5 Change-7.6 ± 11.99-10.0 ± 11.47-9.2 ± 12.07-9.6 ± 13.00-8.7 ± 12.76-9.8 ± 12.01-9.0 ± 11.39-5.5 ± 10.70-6.3 ± 12.07
Day 6 Observed72.9 ± 10.1169.3 ± 10.1171.1 ± 10.7070.2 ± 11.1571.4 ± 11.4372.1 ± 12.3772.5 ± 11.0774.1 ± 12.3373.2 ± 11.31
Day 6 Change-7.1 ± 11.40-10.7 ± 12.20-8.9 ± 11.60-9.8 ± 12.77-8.6 ± 12.26-7.9 ± 13.33-7.5 ± 11.88-6.1 ± 13.61-6.8 ± 14.08
Day 7 Observed73.6 ± 11.1673.2 ± 11.0770.3 ± 11.1771.3 ± 11.6970.4 ± 11.2572.5 ± 10.8969.0 ± 8.9377.1 ± 11.4370.8 ± 11.27
Day 7 Change-6.2 ± 12.37-7.4 ± 11.17-9.5 ± 9.83-9.7 ± 12.29-10.8 ± 11.06-8.5 ± 12.94-11.8 ± 11.89-3.3 ± 12.24-10.4 ± 15.57
Day 8 Observed———————74.6 ± 9.2274.5 ± 13.60
Day 8 Change———————-5.8 ± 10.46-6.2 ± 14.23
Day 9 Observed———————78.4 ± 9.6376.5 ± 14.02
Day 9 Change———————-1.8 ± 10.89-4.2 ± 13.95
Day 10 Observed———————76.9 ± 10.4175.9 ± 11.86
Day 10 Change———————-3.2 ± 10.32-4.5 ± 12.68
Day 11 Observed———————78.1 ± 11.0176.0 ± 9.55
Day 11 Change———————-1.7 ± 10.96-3.9 ± 9.81
Day 12 Observed———————80.0 ± 8.1278.7 ± 9.55
Day 12 Change———————0.3 ± 8.62-1.6 ± 11.95
Day 13 Observed———————83.6 ± 8.3880.8 ± 8.69
Day 13 Change———————4.5 ± 10.291.1 ± 12.01
Day 14 Observed———————84.8 ± 8.53—
Day 14 Change———————5.5 ± 9.72—
PrimaryMean Observed and Change From Screening in Seated Pulse (Bpm): Vital Signs

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · beats per minute (bpm)
Mean Observed and Change From Screening in Seated Pulse (Bpm): Vital Signs
beats per minute (bpm)Inpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Day 1 Observed73.3 ± 10.8968.8 ± 11.9269.2 ± 11.0869.9 ± 12.5770.5 ± 12.2867.6 ± 12.5567.7 ± 12.08——
Day 1 ChangeNA ± NA-6.1 ± 12.75-5.7 ± 12.11-4.9 ± 13.47-4.3 ± 13.63-7.3 ± 13.59-7.0 ± 12.82——
Day 2 Observed70.2 ± 12.7068.8 ± 12.3669.4 ± 11.5766.8 ± 12.6568.7 ± 12.1165.9 ± 12.4166.4 ± 12.55——
Day 2 Change-4.7 ± 14.21-5.9 ± 14.63-5.4 ± 13.64-8.0 ± 14.53-6.2 ± 13.75-9.1 ± 14.30-8.6 ± 14.30——
Day 3 Observed213 ± 70.067.5 ± 12.9768.7 ± 11.5766.6 ± 12.0368.3 ± 12.2365.9 ± 11.6867.4 ± 12.01——
Day 3 Change-5.0 ± 15.10-7.5 ± 15.52-6.4 ± 14.42-8.5 ± 14.77-6.8 ± 14.26-9.2 ± 14.25-7.8 ± 13.70——
Day 4 Observed70.1 ± 13.6068.3 ± 12.4670.6 ± 12.9867.8 ± 13.0070.0 ± 12.0167.8 ± 13.8069.9 ± 12.8070.6 ± 11.8372.4 ± 12.46
Day 4 Change-5.0 ± 16.11-6.8 ± 15.56-4.5 ± 15.43-7.3 ± 15.44-5.0 ± 15.35-6.8 ± 16.59-4.5 ± 14.74-5.2 ± 13.76-3.3 ± 13.25
Day 5 Observed70.9 ± 13.7069.1 ± 11.0371.4 ± 11.7869.0 ± 13.3568.7 ± 11.0868.3 ± 12.8470.0 ± 11.2076.3 ± 13.4973.3 ± 11.44
Day 5 Change-3.4 ± 16.28-5.3 ± 13.57-2.8 ± 13.92-5.2 ± 15.23-5.5 ± 12.29-6.0 ± 15.26-4.4 ± 13.53-0.3 ± 15.14-3.2 ± 13.70
Day 6 Observed70.5 ± 11.2469.8 ± 12.4670.6 ± 12.2468.6 ± 11.4369.7 ± 10.6768.9 ± 13.0571.2 ± 12.4375.2 ± 12.2474.8 ± 13.10
Day 6 Change-3.6 ± 14.98-4.1 ± 14.44-3.3 ± 13.62-5.3 ± 14.37-4.3 ± 12.88-5.1 ± 14.79-2.8 ± 13.55-1.6 ± 14.82-1.6 ± 14.29
Day 7 Observed73.2 ± 13.3473.9 ± 11.7073.6 ± 11.5573.0 ± 12.5373.6 ± 11.7467.4 ± 13.4469.8 ± 11.5973.6 ± 11.4667.1 ± 8.84
Day 7 Change-1.1 ± 16.860.0 ± 13.60-3.1 ± 13.15-3.8 ± 12.93-3.4 ± 11.72-9.5 ± 13.9624 ± 13.29-3.4 ± 15.07-7.7 ± 10.63
Day 8 Observed———————77.7 ± 12.7172.6 ± 13.45
Day 8 Change———————1.6 ± 15.25-3.8 ± 13.48
Day 9 Observed———————79.6 ± 10.7775.1 ± 11.19
Day 9 Change———————2.8 ± 11.80-1.7 ± 11.18
Day 10 Observed———————80.0 ± 13.2977.9 ± 16.42
Day 10 Change———————3.2 ± 14.821.1 ± 16.97
Day 11 Observed———————79.3 ± 13.9374.5 ± 12.49
Day 11 Change———————3.2 ± 13.40-1.4 ± 12.92
Day 12 Observed———————79.7 ± 11.8972.3 ± 11.68
Day 12 Change———————4.0 ± 14.22-3.6 ± 12.29
Day 13 Observed———————76.6 ± 13.2075.5 ± 13.61
Day 13 Change———————2.4 ± 14.790.8 ± 11.75
Day 14 Observed———————76.4 ± 11.66—
Day 14 Change———————2.4 ± 14.27—
PrimaryMean Observed and Change From Screening in Standing Pulse (Bpm): Vital Signs

Baseline vital signs were defined by the assessment value at screening when subjects were not experiencing opioid withdrawal to reduce the potential for variability from the effects of different states of withdrawal that may have been present before dosing on Day 1. Overall screening values are captured in the column "Inpatient: Pre 8AM"; these values were recorded at various times for each participant during the screening visit, not necessarily at 8AM. Serial vital sign assessments required for inpatient visits on days 1-3, either inpatient or outpatient for days 4-7, and outpatient only for days 8-14. Day 14 only required pre-dose vital signs measurement. Day 1 Change, Pre 8AM was prior to the first dose.

Time frame:
Day 1 to Day 14
Reported as:
Mean · beats per minute (bpm)
Mean Observed and Change From Screening in Standing Pulse (Bpm): Vital Signs
beats per minute (bpm)Inpatient: Pre 8AMInpatient: 3.5 hr Post 8AMInpatient: Pre 1PMInpatient: 3.5 hr Post 1PMInpatient: Pre 6PMInpatient: 3.5 hr Post 6PMInpatient: Pre 11PMOutpatient: PredoseOutpatient: 3.5 hr Postdose
Day 1 Observed82.8 ± 13.7479.6 ± 14.2980.1 ± 13.7281.3 ± 14.4281.2 ± 14.1778.9 ± 14.1479.4 ± 14.03——
Day 1 ChangeNA ± NA-1.8 ± 15.18-1.3 ± 14.380.0 ± 16.41-0.1 ± 15.89-2.5 ± 16.25-1.8 ± 16.00——
Day 2 Observed82.4 ± 15.1380.6 ± 15.1981.1 ± 13.7480.5 ± 14.4480.8 ± 14.4678.0 ± 14.6778.4 ± 13.95——
Day 2 Change1.0 ± 16.81-0.5 ± 17.610.0 ± 16.22-0.6 ± 15.44-0.4 ± 16.00-3.3 ± 16.49-3.0 ± 16.62——
Day 3 Observed81.1 ± 14.8279.0 ± 14.2480.0 ± 14.6778.1 ± 15.0979.1 ± 15.3676.4 ± 13.7578.3 ± 13.92——
Day 3 Change-0.2 ± 16.77-2.6 ± 16.59-1.5 ± 15.95-3.3 ± 17.08-2.3 ± 16.27-5.0 ± 16.31-3.2 ± 16.32——
Day 4 Observed81.2 ± 14.9380.1 ± 14.6781.5 ± 15.4079.9 ± 15.4280.8 ± 16.3478.2 ± 15.5280.4 ± 16.1682.0 ± 11.7583.3 ± 15.43
Day 4 Change-0.2 ± 16.09-1.3 ± 16.360.0 ± 16.85-1.5 ± 17.75-0.7 ± 18.62-2.7 ± 17.29-0.2 ± 17.490.9 ± 15.062.1 ± 18.73
Day 5 Observed83.1 ± 16.3181.0 ± 14.0682.3 ± 15.4384.7 ± 51.3980.2 ± 14.8679.5 ± 14.0880.6 ± 14.7485.2 ± 15.2380.8 ± 14.81
Day 5 Change2.4 ± 18.580.3 ± 15.331.6 ± 16.774.2 ± 50.96-0.4 ± 14.80-1.2 ± 15.68-0.1 ± 16.332.8 ± 16.75-1.7 ± 15.90
Day 6 Observed81.7 ± 14.9679.9 ± 14.8981.8 ± 14.9079.5 ± 14.0081.5 ± 13.9380.9 ± 14.5480.9 ± 15.7786.4 ± 15.0884.8 ± 14.77
Day 6 Change1.4 ± 16.05-0.5 ± 16.331.4 ± 15.99-0.9 ± 16.161.0 ± 15.280.4 ± 15.680.4 ± 16.972.6 ± 16.421.6 ± 15.33
Day 7 Observed84.5 ± 15.4480.3 ± 12.4483.4 ± 13.8979.0 ± 13.4580.0 ± 14.4075.1 ± 13.6974.3 ± 12.4183.2 ± 13.1176.9 ± 11.29
Day 7 Change3.5 ± 18.070.2 ± 14.16-0.5 ± 16.23-4.9 ± 14.53-3.6 ± 16.19-8.6 ± 17.80-9.7 ± 16.75-0.5 ± 16.99-4.3 ± 12.54
Day 8 Observed———————85.3 ± 15.0380.7 ± 14.61
Day 8 Change———————2.5 ± 18.08-2.9 ± 15.07
Day 9 Observed———————90.7 ± 16.5182.8 ± 15.66
Day 9 Change———————6.8 ± 15.74-1.1 ± 14.94
Day 10 Observed———————88.7 ± 15.7385.1 ± 17.87
Day 10 Change———————5.1 ± 17.471.6 ± 18.66
Day 11 Observed———————89.3 ± 16.5582.0 ± 16.84
Day 11 Change———————6.4 ± 16.75-0.1 ± 17.81
Day 12 Observed———————90.8 ± 16.2580.0 ± 13.91
0Day 12 Change———————9.2 ± 17.91-1.4 ± 16.75
Day 13 Observed———————86.6 ± 13.5181.4 ± 13.21
Day 13 Change———————6.2 ± 17.171.1 ± 15.14
Day 14 Observed———————87.0 ± 17.66—
Day 14 Change———————7.2 ± 19.63—
PrimaryColumbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior Numbers

The C-SSRS measures both suicidal ideation and suicidal behavior and will be completed to assess lifetime suicidality before first dose of study drug, 3.5 hours after first daily dose of study drug on in-clinic treatment days, and then once a day before dosing during outpatient treatment days. C-SSRS will also be assessed at end of study/discontinuation.

Time frame:
Day 1 to Day 14
Reported as:
Count of participants · Participants
Columbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior Numbers
ParticipantsOL: Lofexidine HCl
Suicidality30
Suicidal ideation27
Suicidal behavior12
Emergence of suicidal ideation2
Emergence of serious suicidal ideation0
Worsening of suicidal ideation2
Emergence of suicidal behavior0
PrimaryClinical Laboratory Test Change From Baseline: Hematology

Hematology Parameters with Shifts in ≥3% of Subjects from Screening to End of Study

Time frame:
Day 1 to Day 14
Reported as:
Count of participants · Participants
Clinical Laboratory Test Change From Baseline: Hematology
ParticipantsBelow Baseline (End of Study)Normal (End of Study)Above Baseline (End of Study)
Hemoglobin (g/dL) : Below (Baseline)25270
Hemoglobin (g/dL) : Normal (Baseline)81248
Hemoglobin (g/dL) : Above (Baseline)019
Hematocrit (%) : Below (Baseline)11230
Hematocrit (%) : Normal (Baseline)612020
Hematocrit (%) : Above (Baseline)01012
Platelet count (x10^9/L) : Below (Baseline)1100
Platelet count (x10^9/L) : Normal (Baseline)416610
Platelet count (x10^9/L) : Above (Baseline)042
Erythrocytes (x10^12/L) : Below (Baseline)14200
Erythrocytes (x10^12/L) : Normal (Baseline)1112216
Erythrocytes (x10^12/L) : Above (Baseline)0811
Erythrocytes distribution width (%) : Below (Baseline)000
Erythrocytes distribution width (%) : Normal (Baseline)015022
Erythrocytes distribution width (%) : Above (Baseline)0822
Mean corpuscular volume (fL) : Below (Baseline)420
Mean corpuscular volume (fL) : Normal (Baseline)01736
Mean corpuscular volume (fL) : Above (Baseline)0413
Leukocytes (x10^9/L) : Below (Baseline)020
Leukocytes (x10^9/L) : Normal (Baseline)216723
Leukocytes (x10^9/L) : Above (Baseline)044
Neutrophils/Leukocytes (%) : Below (Baseline)040
Neutrophils/Leukocytes (%) : Normal (Baseline)216319
Neutrophils/Leukocytes (%) : Above (Baseline)086
Neutrophils (x10^9/L) : Below (Baseline)000
Neutrophils (x10^9/L) : Normal (Baseline)118213
Neutrophils (x10^9/L) : Above (Baseline)033
Lymphocytes/Leukocytes (%) : Below (Baseline)23151
Lymphocytes/Leukocytes (%) : Normal (Baseline)3210310
Lymphocytes/Leukocytes (%) : Above (Baseline)1125
Lymphocytes, absolute (x10^9/L) : Below (Baseline)120
Lymphocytes, absolute (x10^9/L) : Normal (Baseline)31922
Lymphocytes, absolute (x10^9/L) : Above (Baseline)011
Monocytes/Leukocytes (%) : Below (Baseline)000
Monocytes/Leukocytes (%) : Normal (Baseline)115919
Monocytes/Leukocytes (%) : Above (Baseline)0176
Monocytes (x10^9/L) : Below (Baseline)000
Monocytes (x10^9/L) : Normal (Baseline)01927
Monocytes (x10^9/L) : Above (Baseline)021
Eosinophils absolute (x10^9/L) : Below (Baseline)000
Eosinophils absolute (x10^9/L) : Normal (Baseline)01769
Eosinophils absolute (x10^9/L) : Above (Baseline)0107
Eosinophils/Leukocytes (%) : Below (Baseline)000
Eosinophils/Leukocytes (%) : Normal (Baseline)014012
Eosinophils/Leukocytes (%) : Above (Baseline)03119
Prothrombin time (seconds) : Below (Baseline)000
Prothrombin time (seconds) : Normal (Baseline)015420
Prothrombin time (seconds) : Above (Baseline)01714
Activated Partial Thromboplastin Time (seconds) : Below (Baseline)010
Activated Partial Thromboplastin Time (seconds) : Normal (Baseline)015413
Activated Partial Thromboplastin Time (seconds) : Above (Baseline)01918
PrimaryClinical Laboratory Test Change From Baseline: Chemistry

Chemistry Parameters with Shifts in ≥3% of Subjects from Screening to End of Study

Time frame:
Day 1 to Day 14
Reported as:
Count of participants · Participants
Clinical Laboratory Test Change From Baseline: Chemistry
ParticipantsBelow Baseline (End of Study)Normal (End of Study)Above Baseline (End of Study)
Alanine aminotransferase (U/L) : Below (Baseline)000
Alanine aminotransferase (U/L) : Normal (Baseline)015317
Alanine aminotransferase (U/L) : Above (Baseline)01222
Aspartate Aminotransferase (U/L) : Below (Baseline)000
Aspartate Aminotransferase (U/L) : Normal (Baseline)016410
Aspartate Aminotransferase (U/L) : Above (Baseline)01614
Gamma-glutamyl transferase (U/L) : Below (Baseline)9130
Gamma-glutamyl transferase (U/L) : Normal (Baseline)213911
Gamma-glutamyl transferase (U/L) : Above (Baseline)0624
Alkaline phosphatase (U/L) : Below (Baseline)630
Alkaline phosphatase (U/L) : Normal (Baseline)91703
Alkaline phosphatase (U/L) : Above (Baseline)058
Lactate dehydrogenase (U/L) : Below (Baseline)200
Lactate dehydrogenase (U/L) : Normal (Baseline)31647
Lactate dehydrogenase (U/L) : Above (Baseline)0199
Blood urea nitrogen (mg/dL) : Below (Baseline)9281
Blood urea nitrogen (mg/dL) : Normal (Baseline)281275
Blood urea nitrogen (mg/dL) : Above (Baseline)141
Creatinine (mg/dL) : Below (Baseline)29170
Creatinine (mg/dL) : Normal (Baseline)81472
Creatinine (mg/dL) : Above (Baseline)001
Cholesterol (mg/dL) : Below (Baseline)000
Cholesterol (mg/dL) : Normal (Baseline)015318
Cholesterol (mg/dL) : Above (Baseline)01320
Triglycerides (mg/dL) : Below (Baseline)000
Triglycerides (mg/dL) : Normal (Baseline)010740
Triglycerides (mg/dL) : Above (Baseline)01839
Calcium (mg/dL) : Below (Baseline)190
Calcium (mg/dL) : Normal (Baseline)71823
Calcium (mg/dL) : Above (Baseline)020
Sodium (mEq/L) : Below (Baseline)360
Sodium (mEq/L) : Normal (Baseline)31875
Sodium (mEq/L) : Above (Baseline)000
Potassium (mEq/L) : Below (Baseline)020
Potassium (mEq/L) : Normal (Baseline)218311
Potassium (mEq/L) : Above (Baseline)060
Chloride (mEq/L) : Below (Baseline)050
Chloride (mEq/L) : Normal (Baseline)31905
Chloride (mEq/L) : Above (Baseline)001
Carbon dioxide (bicarbonate) (mEq/L) : Below (Baseline)000
Carbon dioxide (bicarbonate) (mEq/L) : Normal (Baseline)31347
Carbon dioxide (bicarbonate) (mEq/L) : Above (Baseline)0528
Glucose (mg/dL) : Below (Baseline)050
Glucose (mg/dL) : Normal (Baseline)113035
Glucose (mg/dL) : Above (Baseline)01914
Phosphate (mg/dL) : Below (Baseline)140
Phosphate (mg/dL) : Normal (Baseline)613822
Phosphate (mg/dL) : Above (Baseline)1266
Protein (g/dL) : Below (Baseline)010
Protein (g/dL) : Normal (Baseline)01904
Protein (g/dL) : Above (Baseline)063
Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Below (Baseline)11180
Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Normal (Baseline)161493
Thyroid Stimulating Hormone-3rd Generation (TSH Thyrotropin)(mU/L) : Above (Baseline)061
PrimaryClinical Laboratory Test Change From Baseline: Urinalysis
Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Clinical Laboratory Test Change From Baseline: Urinalysis
ParticipantsBelow Baseline (End of Study)Normal (End of Study)Above Baseline (End of Study)
Erythrocytes (/HPF) : Below (Baseline)000
Erythrocytes (/HPF) : Normal (Baseline)013630
Erythrocytes (/HPF) : Above (Baseline)02813
Leukocytes (/HPF) : Below (Baseline)000
Leukocytes (/HPF) : Normal (Baseline)017515
Leukocytes (/HPF) : Above (Baseline)0134
Specific Gravity : Below (Baseline)020
Specific Gravity : Normal (Baseline)01883
Specific Gravity : Above (Baseline)0131
pH : Below (Baseline)000
pH : Normal (Baseline)02041
pH : Above (Baseline)020
PrimarySafety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of Study

For each 12-lead ECG obtained during the study, the investigator made an overall interpretation of the ECG (normal, abnormal NCS, and abnormal CS). Shifts from normal at baseline to abnormal NCS and abnormal CS at the end of study predose and postdose assessments were summarized.

Time frame:
Day 1 and Day 14
Reported as:
Count of participants · Participants
Safety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of Study
ParticipantsBaseline Finding: Normal (OL: Lofexidine HCl)Baseline Finding: Abnormal (NCS) (OL: Lofexidine HCl)Baseline Finding: Abnormal (CS) (OL: Lofexidine HCl)Total (OL: Lofexidine HCl)
Day 1 Post 8am Dose — Normal139160155
Day 1 Post 8am Dose — Abnormal (NCS)41870128
Day 1 Post 8am Dose — Abnormal (CS)0000
End of Study Pre Dose — Normal83200103
End of Study Pre Dose — Abnormal (NCS)1938057
End of Study Pre Dose — Abnormal (CS)1001
End of Study Post Dose — Normal77260103
End of Study Post Dose — Abnormal (NCS)4147088
End of Study Post Dose — Abnormal (CS)2002

Adverse events

Collected over AEs will be followed starting with dosing on Day 1 through Day 14, and will be evaluated as well on a 30-day post-last dose follow-up phone call.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OL: Lofexidine HCl0/286 (0%)2/286 (0.7%)270/286 (94.4%)
Most frequent serious events
Most frequent serious events
EventOL: Lofexidine HCl
DelusionPsychiatric disorders1/286
Cerebrovascular accidentNervous system disorders1/286
Most frequent other events
Showing 10 of 20
Most frequent other events
EventOL: Lofexidine HCl
InsomniaPsychiatric disorders144/286
AnxietyPsychiatric disorders107/286
Orthostatic hypotensionVascular disorders96/286
HypotensionVascular disorders84/286
BradycardiaCardiac disorders72/286
DiarrheaGastrointestinal disorders54/286
NauseaGastrointestinal disorders50/286
DizzinessNervous system disorders47/286
SedationNervous system disorders46/286
HeadacheNervous system disorders43/286

Baseline characteristics

Age, Continuous
Age, Continuous(years)OL: Lofexidine HCl
Mean37.5 ± 10.32
Sex: Female, Male
Sex: Female, Male(Participants)OL: Lofexidine HCl
Female98
Male188
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OL: Lofexidine HCl
Hispanic or Latino44
Not Hispanic or Latino242
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OL: Lofexidine HCl
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander1
Black or African American62
White218
More than one race0
Unknown or Not Reported5
Height (cm)
Height (cm)(cm)OL: Lofexidine HCl
Mean173.2 ± 9.99
Weight (kg)
Weight (kg)(kg)OL: Lofexidine HCl
Mean78.4 ± 17.96
BMI (kg/m^2)
BMI (kg/m^2)(kg/m^2)OL: Lofexidine HCl
Mean26.1 ± 5.43
08

Study locations

18 sites
  • Little Rock, Arkansas 72211, United States
  • Springdale, Arkansas 72764, United States
  • San Diego, California 92103, United States
  • Fort Lauderdale, Florida 33308, United States
  • Hollywood, Florida 33021, United States
  • Orlando, Florida 32801, United States
  • Atlanta, Georgia 30331, United States
  • Winfield, Illinois 60190, United States
  • Lake Charles, Louisiana 70629, United States
  • Rockville, Maryland 20853, United States
  • Flowood, Mississippi 39232, United States
  • Saint Louis, Missouri 63141, United States
  • New York, New York 10019, United States
  • Dayton, Ohio 45417, United States
  • Portland, Oregon 97214, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • North Charleston, South Carolina 29405, United States
  • Orem, Utah 84058, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Sep 2015, 7 months.

Results were first posted in Apr 2021, 5 years 7 months after primary completion. A results delay was requested in Oct 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2015
First posted
Feb 16, 2015
StartActual
Feb 2015
Primary completionActual
Sep 2015
CompletionActual
Oct 2015
Results delay requested
Oct 4, 2016
Results first posted
Apr 26, 2021
Last update
Mar 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02363998
Lead sponsor
USWM, LLC (dba US WorldMeds)
Responsible party
Sponsor
First posted
Feb 16, 2015
Start date
Feb 2015
Primary completion
Sep 2015
Completion
Oct 2015
Results posted
Apr 26, 2021
Last update
Mar 22, 2022

Study contacts

Charles W Gorodetzky, MD, PhD
study director · US WorldMeds

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lofexidine

Start the discussion